owe
uniqu
advantag
simplic
safeti
scalabl
possibl
repeat
administr
dna
vaccin
repres
appeal
competit
immun
approach
wide
array
condit
includ
limit
infecti
diseas
cancer
immunotherapi
despit
excit
efficaci
observ
preclin
studi
dna
vaccin
face
challeng
induc
strong
immun
respons
human
unexpect
poor
immunogen
sever
hamper
translat
dna
vaccin
investig
medic
licens
product
overcom
obstacl
tremend
effort
made
improv
antigen
express
enhanc
immunogen
among
endeavor
vivo
dna
electropor
ep
prove
breakthrough
technolog
capabl
mediat
effici
dna
uptak
result
enhanc
antigen
express
vaccin
immunogen
epmedi
dna
deliveri
becom
one
major
platform
use
clinic
trial
evalu
dna
vaccin
human
chapter
addit
ep
deliveri
progress
made
dna
vaccin
develop
includ
plasmid
optim
antigen
design
immunolog
adjuv
also
review
final
use
dna
vaccin
context
clinic
trial
infecti
diseas
cancer
immunotherapi
summar
specif
strategi
allow
dna
vaccin
overcom
antigen
divers
viral
infect
break
immun
toler
cancer
therapi
explor
base
advantag
dna
vaccin
immens
progress
led
electroporationmedi
vaccin
deliveri
dna
vaccin
appear
potenti
fundament
transform
vaccin
field
provid
import
benefit
prevent
cure
diseas
wolff
colleagu
first
demonstr
longterm
gene
express
could
achiev
simpli
direct
inject
plasmid
dna
mous
skelet
muscl
wolff
et
al
two
year
later
tang
et
al
report
vivo
deliveri
plasmid
dna
encod
human
growth
hormon
hgh
result
product
detect
level
hgh
host
mice
importantli
inocul
mice
develop
antihgh
antibodi
suggest
immunolog
use
dna
tang
et
al
pioneer
observ
engend
great
enthusiasm
use
dna
immun
infecti
diseas
well
applic
gene
therapi
immunolog
potenti
dna
confirm
sever
independ
preclin
studi
demonstr
dna
immun
could
result
protect
infecti
diseas
immun
anim
moss
action
dna
immun
involv
intramuscular
subcutan
inject
dna
plasmid
encod
antigen
interest
express
control
eukaryot
promot
upon
administr
plasmid
dna
vivo
express
antigen
stimul
host
immun
system
elicit
respons
third
gener
platform
dna
vaccin
distinct
advantag
vaccin
approach
dna
vaccin
induc
humor
cellular
immun
respons
make
distinct
convent
inactiv
vaccin
subunit
vaccin
addit
plasmid
dna
number
unmethyl
cpg
motif
due
bacteri
origin
capabl
stimul
innat
immun
respons
via
tolllik
receptor
abil
activ
arm
immun
system
b
cell
h
cell
cytotox
cell
mean
dna
vaccin
platform
potenti
prophylact
also
therapeut
applic
unlik
tradit
prophylact
vaccin
prevent
infect
occur
therapeut
dna
vaccin
use
immunotherapi
treat
chronic
viral
infect
cancer
direct
kill
latent
infect
cell
mutat
tumor
cell
dna
vaccin
also
shown
benign
safeti
profil
inject
plasmid
encod
select
gene
pathogen
elimin
risk
pathogen
infect
revers
virul
safeti
concern
associ
live
attenu
vaccin
importantli
plasmid
dna
vaccin
noninfecti
elicit
immun
respons
sole
specif
antigen
encod
transgen
rather
plasmid
result
antidna
vector
respons
observ
therebi
allow
repeat
vaccin
administr
without
weaken
specif
immun
respons
featur
critic
prime
boost
regimen
commonli
use
approach
enhanc
vaccin
immunogen
anoth
advantag
make
dna
vaccin
competit
option
eas
design
manufactur
advanc
gene
synthesi
recombin
dna
technolog
allow
flexibl
rapid
alter
express
immunogen
largescal
product
plasmid
complet
within
short
period
time
make
dna
vaccin
particularli
suitabl
respond
pandem
outbreak
final
dna
vaccin
stabl
resist
temperatur
extrem
vaccin
form
great
benefit
storag
transport
distribut
especi
resourcelimit
region
despit
posit
characterist
superb
efficaci
observ
preclin
studi
dna
vaccin
slow
demonstr
similar
success
human
unforeseen
poor
immunogen
observ
earli
clinic
trial
disappoint
pose
formid
challeng
dna
vaccin
licensur
howev
sever
dna
vaccin
approv
anim
health
first
one
develop
fort
dodg
laboratori
west
nile
viru
infect
hors
approv
us
depart
agricultur
usda
second
dna
vaccin
apexihn
novarti
anim
health
licens
canada
prevent
hematopoiet
necrosi
viru
infect
farm
salmon
trout
therapeut
cancer
vaccin
oncept
merial
design
treat
dog
melanoma
approv
usda
final
inject
dna
plasmid
lifetid
sw
vgx
anim
health
encod
porcin
growth
hormon
releas
hormon
ghrh
licens
australia
gene
therapi
use
breed
age
sow
increas
number
piglet
litter
approv
plasmid
commerci
product
veterinari
practic
encourag
shed
light
human
dna
vaccin
develop
exampl
licens
therapeut
vaccin
canin
malign
melanoma
develop
use
human
tyrosinas
melanoma
associ
antigen
immunogen
immun
dog
human
tyrosinas
elicit
strong
immun
respons
dog
melanoma
significantli
prolong
live
dog
advanc
diseas
bergman
et
al
success
vaccin
support
concept
use
xenogen
protein
break
central
immun
toler
cancer
vaccin
develop
liu
addit
insight
gain
success
dna
vaccin
veterinari
practic
dna
scalingup
might
potenti
hindranc
dna
vaccin
effect
human
extrapol
impract
high
dose
dna
vaccin
would
requir
use
human
subject
order
reproduc
vaccin
efficaci
obtain
mice
tregon
kinnear
howev
clinic
benefit
observ
larg
anim
includ
hors
pig
suggest
size
human
may
reason
variou
disappoint
clinic
result
liu
light
aforement
advantag
dna
vaccin
encourag
success
veterinari
medicin
great
effort
made
translat
dna
immun
clinic
novel
strategi
explor
enhanc
immunogen
sinc
first
human
studi
calarota
et
al
numer
clinic
trial
dna
vaccin
target
wide
spectrum
diseas
perform
current
underway
follow
section
variou
aspect
relat
dna
vaccin
develop
includ
work
mechan
rout
deliveri
advanc
made
optim
dna
vaccin
immunogen
usag
applic
infecti
diseas
cancer
treatment
address
upon
intramuscular
intraderm
inject
plasmid
dna
intern
myocyt
keratinocyt
locat
site
vaccin
administr
plasmid
encod
antigen
express
intracellularli
use
host
cell
machineri
howev
sinc
myocyt
keratinocyt
profession
antigen
present
cell
apc
express
costimulatori
molecul
unabl
product
stimul
cytotox
lymphocyt
ctl
activ
order
prime
cellular
respons
intracellularli
produc
antigen
must
releas
extracellular
matrix
either
secret
cell
lysi
releas
antigen
engulf
apc
load
onto
major
histocompat
complex
mhc
class
molecul
lead
activ
cell
uptak
mechan
differ
occur
exogen
protein
thu
term
crossprim
liu
dna
plasmid
also
directli
transfect
apc
migrat
inject
site
express
apc
antigen
cleav
peptid
upload
onto
mhc
ii
molecul
lead
activ
ctl
h
cell
addit
antigen
releas
myocyt
keratinocyt
captur
b
lymphocyt
lead
activ
humor
immun
addit
stimul
adapt
immun
system
dna
plasmid
also
trigger
activ
innat
immun
plasmid
deriv
bacteria
contain
hypomethyl
cpg
dinucleotid
motif
immunostimulatori
rare
seen
eukaryot
cpg
motif
bind
tolllik
receptor
transmembran
protein
found
number
immun
cell
includ
dendrit
cell
dc
b
cell
natur
killer
nk
cell
activ
lead
cascad
proinflammatori
respons
result
product
variou
cytokin
includ
type
interferon
ifn
interleukin
il
tumor
necrosi
factoralpha
addit
pathway
doublestrand
structur
plasmid
detect
dna
sensor
cytosol
trigger
activ
stimul
interferon
gene
sting
tankbind
kinas
pathway
lead
type
interferon
ifn
product
histor
variou
administr
rout
includ
intramuscular
intraderm
subcutan
intranas
vagin
oral
intraven
rout
test
liu
tregon
kinnear
order
elicit
desir
immun
respons
dna
immun
select
appropri
deliveri
method
depend
multipl
factor
includ
optimum
express
immunogen
feasibl
toler
among
consid
deliveri
approach
intramuscular
im
inject
princip
rout
choic
dna
vaccin
due
fact
skelet
muscl
readili
access
highli
effect
take
dna
furthermor
myocyt
energi
rich
postmitot
cell
capabl
sustain
longterm
transgen
express
elicit
durabl
immun
aurisicchio
et
al
tregon
kinnear
addit
im
inject
intraderm
id
deliveri
also
consid
effect
pathway
vaccin
greater
eas
access
also
promin
presenc
larg
amount
immun
cell
dermi
includ
dendrit
cell
langerhan
cell
migrat
lymphocyt
im
id
two
major
administr
rout
use
preclin
studi
clinic
trial
dna
deliveri
studi
suggest
natur
immun
respons
could
driven
vaccin
administr
rout
exampl
due
enrich
antigen
present
cell
skin
id
rout
believ
preferenti
induc
cellular
immun
respons
result
direct
transfect
apc
hand
im
inject
equal
induc
humor
cellular
immun
via
direct
transfect
crossprim
mechan
howev
recent
clinic
trial
hivspecif
dna
vaccin
deliv
via
either
im
id
rout
differ
induc
immun
respons
observ
enama
et
al
administr
plasmid
dna
must
success
overcom
seri
barrier
mount
desir
immun
respons
compar
viral
vector
uptak
nake
dna
somat
cell
ineffici
iminject
dna
actual
transfect
cell
liu
enter
cell
plasmid
dna
need
transloc
nucleu
dna
transcript
occur
howev
effici
intracellular
movement
low
less
plasmid
dna
enter
cytosol
eventu
transcrib
tregon
kinnear
moreov
prior
arriv
nucleu
dna
cytosol
subject
degrad
nucleas
digest
final
process
protein
synthesi
mrna
translat
effici
also
modul
factor
presenc
kozak
sequenc
codon
usag
overcom
obstacl
sever
approach
focus
augment
dna
uptak
maxim
protein
express
enhanc
antigen
immunogen
develop
test
clinic
trial
sever
dna
deliveri
method
includ
gene
gun
jet
inject
electropor
ep
cation
polym
liposom
use
clinic
trial
given
inclus
extra
chemic
compon
may
delay
licensur
vaccin
due
concern
inflammatori
profil
agent
devicemedi
deliveri
consid
univers
prefer
approach
enhanc
dna
uptak
tregon
kinnear
among
devicemedi
approach
ep
highest
transfect
effici
achiev
remark
progress
dna
vaccin
deliveri
aurisicchio
et
al
best
et
al
ep
technolog
initi
devis
vitro
transfect
see
also
chap
gene
deliveri
electropor
vitro
mechan
mechan
ep
involv
use
control
electr
puls
open
transient
pore
cell
membran
neg
charg
dna
molecul
gain
access
cytoplasm
cell
membran
permeabil
short
period
time
rapidli
close
electr
treatment
termin
return
cell
origin
state
ep
proven
power
technolog
result
increas
plasmid
uptak
subsequ
antigen
express
compar
nake
dna
vaccin
aurisicchio
et
al
furthermor
ep
addit
benefit
caus
tissu
damag
lead
local
inflamm
releas
cytokin
fioretti
et
al
adjuv
effect
ep
consequ
promot
induct
innat
adapt
immun
respons
potenti
immunogen
deliv
dna
ep
technolog
safe
well
toler
bagarazzi
et
al
common
minor
side
effect
observ
clinic
trial
local
injectionsit
pain
discomfort
associ
short
muscl
contract
trigger
electr
puls
believ
ep
repres
promis
technolog
dna
deliveri
aurisicchio
et
al
recent
applic
im
inject
follow
ep
deliveri
becom
one
major
platform
use
clinic
trial
evalu
dna
vaccin
human
howev
note
ep
technolog
intrins
limit
ep
approach
requir
penetr
sever
sharp
needlelik
electrod
subject
bodi
follow
introduct
transient
electr
puls
result
ep
procedur
less
conveni
invas
sometim
intimid
potenti
reduc
patient
complianc
compar
simpl
im
inject
furthermor
ep
procedur
demand
develop
practic
afford
devic
provid
adequ
train
health
profession
administ
vaccin
immun
respons
dna
vaccin
shown
depend
antigen
express
tregon
kinnear
therefor
optim
antigen
express
key
improv
vaccin
perform
plasmid
codon
optim
one
approach
augment
express
refer
chang
antigen
code
sequenc
via
synonym
substitut
wild
type
select
sequenc
abund
trna
cytosol
transfect
cell
codon
optim
advers
rare
codon
avoid
secondari
structur
mrna
minim
therefor
protein
express
increas
severalfold
addit
codon
optim
variou
manipul
dna
sequenc
perform
modul
antigen
intracellular
process
immun
respons
prime
exampl
ad
nuclear
local
signal
plasmid
help
direct
dna
nucleu
transcript
purpos
introduc
cellular
immun
ubiquitin
code
sequenc
incorpor
dna
vaccin
enhanc
protein
degrad
antigen
peptid
product
proteasom
leifert
et
al
humor
immun
desir
antigen
code
region
modifi
ad
leader
sequenc
capabl
guid
express
antigen
undergo
proper
fold
endoplasm
reticulum
er
export
secretori
pathway
releas
extracellular
matrix
present
b
lymphocyt
apc
fioretti
et
al
due
bacteri
origin
plasmid
dna
carri
natur
occur
adjuv
coinject
antigenencod
plasmid
empti
vector
carri
insert
shown
induc
stronger
immun
respons
use
antigenencod
plasmid
alon
liu
enhanc
immunogen
attribut
adjuv
effect
hypomethyl
cpg
oligodinucleotid
bind
therebi
stimul
innat
immun
creat
inflammatori
milieu
boost
adapt
immun
respons
encod
antigen
liu
attempt
mimic
adjuv
effect
addit
cpg
motif
use
dna
vaccin
platform
result
enhanc
immun
respons
altern
instead
use
incorpor
cpg
sequenc
trigger
tlr
activ
coadministr
addit
plasmid
express
ligand
signal
molecul
shown
improv
immunogen
dna
vaccin
kwissa
et
al
one
disadvantag
use
inflammatori
adjuv
boost
vaccin
immunogen
sequenti
fashion
ie
innat
immun
activ
follow
adapt
immun
activ
possibl
acut
inflamm
induc
adjuv
may
result
clearanc
transfect
cell
suffici
antigen
express
tregon
kinnear
avoid
time
issu
genet
adjuv
investig
enhanc
vaccin
immunogen
genet
adjuv
refer
immunoregulatori
cytokin
protein
encod
addit
plasmid
commonli
use
genet
adjuv
includ
granulocytemacrophag
colonystimul
factor
gmcsf
intercellular
adhes
molecul
icami
heat
shock
protein
fioretti
et
al
tregon
kinnear
plasmid
encod
genet
adjuv
normal
deliv
coinject
plasmid
encod
vaccin
altern
adjuv
transgen
tailor
encod
ci
antigen
code
sequenc
dna
vector
well
fioretti
et
al
way
peak
express
genet
adjuv
match
antigen
express
lead
synergist
respons
moreov
effect
tend
specif
tlrtype
adjuv
reactogen
tregon
kinnear
convent
licens
influenza
flu
vaccin
tradit
made
grow
recommend
season
vaccin
strain
egg
follow
inactiv
attenu
inactiv
attenu
viru
vaccin
promot
immun
respons
prevent
infect
ident
similar
virus
howev
due
antigen
divers
annual
recommend
flu
vaccin
becom
ineffect
new
strain
emerg
order
avoid
frequent
composit
adjust
emerg
influenza
strain
new
vaccin
platform
capabl
induc
univers
immun
respons
broad
spectrum
influenza
strain
greatli
need
viral
surfac
protein
primari
target
prophylact
vaccin
develop
crucial
role
initi
infect
promin
display
virion
surfac
howev
due
host
immun
pressur
surfac
protein
constantli
evolv
high
degre
variabl
make
difficult
develop
univers
vaccin
thank
versatil
eas
rapid
alter
express
immunogen
dna
vaccin
strategi
great
potenti
overcom
influenza
antigen
divers
exampl
novel
synthet
consensu
sequenc
technolog
develop
broaden
effect
vaccin
cover
variant
strain
influenza
display
antigen
alter
hemagglutinin
ha
specif
use
combin
extens
genet
data
comput
algorithm
gene
sequenc
encod
ha
protein
larg
number
circul
influenza
strain
analyz
subsequ
new
arrang
dna
sequenc
creat
result
averag
gene
sequenc
ha
protein
synthet
consensu
dna
sequenc
substanti
similar
differ
encod
natur
occur
circul
variant
upon
deliveri
synthet
consensu
plasmid
dna
vivo
express
artifici
unmatch
ha
led
gener
neutral
antibodi
capabl
recogn
wide
varieti
relat
strain
choo
et
al
abil
synthet
consensu
plasmidgener
dna
vaccin
crossprotect
test
ferret
sera
deriv
immun
anim
exhibit
protect
neutral
four
subclad
protect
level
attain
previous
strainmatch
influenza
vaccin
candid
choo
et
al
synthet
consensu
dna
vaccin
target
variant
strain
influenza
test
phase
clinic
trial
well
known
vaccineinduc
influenza
neutral
antibodi
invari
target
globular
head
region
influenza
hemagglutinin
ha
larg
strain
specif
hand
local
region
ha
stem
found
structur
conserv
among
type
influenza
virus
antibodi
specif
region
broadli
neutral
although
ha
stemspecif
antibodi
identifi
human
possibl
specif
elicit
vaccin
primeboost
strategi
involv
dna
vaccin
develop
shown
abl
induc
broadli
neutral
antibodi
wei
et
al
specif
vaccin
plasmid
dna
encod
influenza
hemagglutinin
boost
season
vaccin
replicationdefect
adenoviru
vector
encod
ha
stimul
product
broadli
neutral
antibodi
specif
conserv
stem
region
primeboost
combin
increas
neutral
divers
strain
date
offer
crossprotect
diverg
virus
mice
ferret
wei
et
al
base
result
primeboost
strategi
test
human
studi
evalu
abil
stimul
broadli
neutral
antibodi
ledgerwood
et
al
found
dna
prime
monoval
inactiv
vaccin
miv
boost
interv
induc
protect
hemagglutin
inhibit
hai
titer
individu
moreov
compar
anoth
phase
trial
miv
vaccin
use
prime
immun
homolog
primeboost
dnamiv
heterolog
prime
boost
approach
demonstr
stronger
abil
elicit
humor
immun
evidenc
fourfold
increas
hai
titer
ledgerwood
et
al
result
obtain
studi
suggest
dna
vaccin
prime
follow
miv
viral
vector
boost
promis
approach
develop
univers
influenza
vaccin
human
addit
surfac
protein
viral
antigen
inaccess
antibodi
nucleocapsid
protein
np
matrix
protein
also
includ
immunogen
dna
vaccin
gener
intern
structur
protein
highli
conserv
among
variant
strain
ctl
rais
conserv
intern
protein
confer
crossprotect
divers
relat
strain
exampl
preclin
studi
dna
vaccin
target
np
influenza
strain
elicit
broadli
effect
ctl
provid
crossprotect
challeng
strain
aris
three
decad
later
find
suggest
immun
respons
surfac
intern
viral
protein
provid
optim
protect
therefor
order
obtain
greatest
efficaci
conceptu
reason
includ
multipl
plasmid
influenza
dna
vaccin
cocktail
induc
antibodi
ha
protein
cytotox
immun
viral
np
protein
case
influenza
tradit
manufactur
process
licens
flu
vaccin
labor
intens
time
consum
imped
imper
respons
outbreak
crisi
occur
swineorigin
influenza
caus
global
pandem
licens
pandem
vaccin
form
kill
virus
could
releas
half
year
world
health
organ
announc
global
outbreak
contrast
virtu
simplic
manufactur
investig
pandem
dna
vaccin
quickli
made
avail
month
earlier
licens
pandem
vaccin
test
phase
clinic
trial
dna
vaccin
elicit
humor
cellular
immun
pandem
strain
immun
respons
could
boost
licens
pandem
vaccin
becam
avail
crank
et
al
result
deriv
phase
clinic
trial
suggest
dna
vaccin
particular
valu
pandem
set
control
outbreak
emerg
infecti
diseas
sinc
initi
identif
earli
scientif
commun
work
dilig
toward
safe
efficaci
vaccin
render
steril
immun
hiv
infect
howev
despit
tremend
effort
made
past
three
decad
success
hiv
vaccin
remain
elus
histor
larg
number
infecti
diseas
live
attenu
kill
whole
viru
prove
first
second
best
approach
success
vaccin
develop
gallo
howev
neither
includ
hiv
vaccin
due
safeti
concern
attenu
hiv
would
caus
aid
one
certain
viru
particl
would
complet
inactiv
date
two
subunit
vaccin
name
hepat
b
viru
hbv
vaccin
human
papillomaviru
hpv
vaccin
approv
clinic
use
howev
similar
success
reproduc
viral
diseas
includ
hiv
infect
note
hbv
recombin
protein
differ
mani
viral
recombin
protein
regard
abil
form
particl
featur
may
render
hbv
recombin
protein
super
immunogen
liu
nevertheless
field
remain
far
less
experienc
recombin
subunit
vaccin
approach
henc
reason
long
period
time
formul
hiv
vaccin
might
limit
hiv
protein
dna
form
gallo
first
clinic
trial
dna
vaccin
hiv
perform
infect
patient
immun
plasmid
construct
encod
nef
rev
tat
regulatori
protein
immun
result
detect
transientspecif
cytotox
eight
nine
patient
immun
calarota
et
al
sinc
clinic
studi
use
improv
formul
deliveri
strategi
conduct
sever
phase
trial
effort
improv
immunogen
addit
plasmid
encod
given
togeth
dna
vaccin
encod
hiv
env
gag
pol
protein
inclus
molecular
adjuv
led
increas
magnitud
breath
cellular
humor
immun
felber
et
al
recent
sever
vaccin
use
dna
prime
combin
differ
boost
also
evalu
boost
use
trial
either
viral
vector
recombin
modifi
vaccinia
ankara
rmva
recombin
adenoviru
rade
recombin
vesicular
stomat
viru
rvsv
express
env
form
purifi
recombin
protein
felber
et
al
rational
use
dna
prime
protein
boost
approach
base
observ
dna
vaccin
suit
elicit
strong
cellular
immun
wherea
protein
immun
preferenti
induc
antibodi
respons
felber
et
al
largescal
efficaci
trial
carri
thailand
trial
use
similar
primeboost
schedul
prime
dna
hiv
env
gag
pro
gene
introduc
canarypox
vector
rather
nake
dna
vaccin
although
dna
uptak
effici
mediat
viral
vector
could
higher
nake
dna
one
potenti
disadvantag
use
viral
vector
preexist
antivector
immun
may
dampen
effect
prime
immun
issu
perceiv
fail
step
also
refer
merck
trial
nonetheless
trial
one
demonstr
transient
modest
protect
benefit
notabl
limit
protect
appear
correl
humor
respons
nevertheless
consensu
agreement
reach
field
effect
hiv
vaccin
afford
humor
cellular
immun
wherebi
neutral
antibodi
block
viru
entri
site
infect
ctl
elimin
infiltr
infect
felber
et
al
addit
applic
dna
vaccin
hiv
potenti
use
therapi
use
simian
immunodefici
viru
siv
macaqu
model
therapeut
dna
vaccin
induc
potent
cellular
respons
viral
rebound
observ
mani
month
cessat
antiretrovir
therapi
art
felber
et
al
similarli
tenfold
reduct
viremia
delay
kinet
viral
rebound
observ
human
studi
test
therapeut
dna
vaccin
mylvaganam
et
al
howev
clinic
benefit
posit
result
still
unclear
hypothes
optim
boost
preexist
hivspecif
immun
respons
therapeut
vaccin
need
combin
therapeut
approach
check
point
inhibitor
mylvaganam
et
al
applic
dna
vaccin
limit
influenza
hiv
infect
date
viral
diseas
dna
vaccin
enter
clinic
trial
list
clinic
trial
target
viral
diseas
summar
tabl
among
trial
therapeut
dna
vaccin
target
cytomegaloviru
cmv
reactiv
cmvseroposit
hematopoiet
stem
cell
transplant
recipi
enter
pivot
phase
iii
studi
vaccin
consist
two
plasmid
express
cmv
antigen
glycoprotein
b
gb
phosphoprotein
previou
phase
ii
trial
cmv
dna
vaccin
provid
initi
evid
safeti
reveal
signific
reduct
viral
load
extend
period
time
onset
viremia
smith
et
al
thought
time
lymphocyt
act
sentinel
recogn
elimin
continu
aris
neoplast
cell
indirect
evid
support
notion
immunotherapi
could
use
altern
treatment
cancer
come
observ
incid
malign
kaposi
sarcoma
nonhodgkin
lymphoma
invas
cervic
cancer
increas
significantli
immunocompromis
patient
presenc
h
cell
tumor
microenviron
also
found
favor
prognost
factor
mani
differ
cancer
moreov
tumor
infiltr
lymphocyt
til
success
use
adopt
cell
transfer
treatment
metastat
melanoma
result
tumor
regress
thu
one
effect
approach
develop
cancer
immunotherapi
activ
immun
system
vaccin
gener
cytotox
lymphocyt
capabl
elimin
tumor
cell
dna
immun
particular
interest
develop
therapeut
cancer
vaccin
base
gener
cell
ideal
vaccinationactiv
cell
abl
recogn
tumorassoci
antigen
taa
initi
target
kill
malign
cell
howev
tumor
caus
loss
growth
control
normal
tissu
thu
express
selfantigen
either
recogn
weakli
reactiv
immun
system
phenomenon
describ
immun
toler
inher
mechan
prevent
autoimmun
immun
system
attack
host
cell
tissu
therefor
one
key
element
improv
dna
vaccin
efficaci
formul
vaccin
immunogen
cancer
antigen
prime
cell
immun
respons
date
larg
number
cancer
antigen
identifi
base
express
pattern
cancer
antigen
classifi
four
categori
first
group
consist
antigen
known
cancertesti
ct
antigen
antigen
express
particular
tumor
cell
immun
privileg
germ
line
tissu
normal
adult
cell
melanomaassoci
antigen
mage
new
york
esophag
squamou
cell
carcinoma
exampl
group
second
class
antigen
larg
divers
group
includ
protein
found
increas
level
tumor
compar
normal
healthi
cell
tissu
antigen
term
overexpress
selfprotein
repres
member
famili
prostatespecif
membran
antigen
psma
human
telomeras
revers
transcriptas
htert
human
epiderm
growth
factor
receptor
antigen
specif
certain
type
tissu
share
tumor
normal
tissu
origin
call
differenti
antigen
prototyp
class
includ
tyrosinas
melanamelanoma
antigen
recogn
cell
molecul
express
melanoma
normal
melanocyt
final
antigen
found
exclus
tumor
cell
normal
tissu
call
tumorspecif
antigen
tsa
uniqu
tumor
antigen
gener
somat
mutat
result
aberr
gene
express
mutat
protein
usual
play
import
role
process
cancer
develop
thu
select
surviv
yang
et
al
tumorspecif
antigen
present
tumor
cell
readili
recogn
host
immun
system
ideal
target
cancer
vaccin
develop
howev
incorpor
tumorspecif
antigen
vaccin
design
complic
fact
tumor
type
induc
variou
distinct
point
mutat
make
difficult
identifi
broadli
applic
tumorspecif
antigen
vaccin
yang
et
al
viral
antigen
carri
oncogen
virus
hpv
hbv
repres
anoth
class
tumorspecif
antigen
exampl
two
hpv
viral
oncoprotein
requir
induct
mainten
cellular
transform
consist
coexpress
hpvassoci
cancer
exclus
presenc
virusinfect
cell
natur
foreign
origin
render
vaccin
target
protein
less
vulner
central
immun
toler
undesir
ontarget
offtumor
cytotox
although
cancer
antigen
potenti
activ
immun
system
result
tumor
regress
applic
human
cancer
vaccin
hamper
inher
poor
immunogen
cancer
antigen
tumor
relat
rather
tumor
specif
unrespons
selfantigen
caus
immun
toler
major
roadblock
cancer
vaccin
develop
thu
press
need
innov
cancer
vaccin
design
immun
toler
circumv
one
way
induc
immun
tissu
specif
differenti
antigen
cancer
cell
vaccin
xenogen
version
antigen
name
suggest
xenogen
antigen
homolog
cancer
antigen
origin
speci
foreign
host
xenogen
dna
vaccin
incorpor
plasmid
dna
encod
protein
homolog
two
speci
ideal
xenoantigen
suffici
differ
selfantigen
order
immunogen
must
hand
also
preserv
optim
homolog
rang
selfprotein
secur
crossreact
induc
immun
respons
strike
exampl
use
xenogen
antigen
break
immun
toler
evidenc
licens
canin
melanoma
dna
vaccin
therapeut
agent
advanc
melanoma
bergman
et
al
vaccin
consist
dna
encod
human
version
tyrosinas
enabl
dog
immun
system
break
toler
dog
tyrosinas
mount
effect
respons
concept
use
xenoantigen
enhanc
vaccin
immunogen
also
support
recent
preclin
studi
mice
immun
human
dna
vaccin
protect
challeng
murin
colon
cancer
immun
mous
dna
soong
et
al
therapeut
model
establish
tumor
also
well
control
treatment
dna
therapi
tumor
bear
mice
compar
dna
mice
vaccin
dna
plasmid
exhibit
increas
tcell
compar
vaccin
dna
soong
et
al
associ
recognit
anoth
strateg
antigen
design
aim
break
central
immun
toler
rational
approach
introduc
addit
gene
code
sequenc
dna
vaccin
fusion
protein
contain
cancer
antigen
associ
peptid
express
peptid
moieti
epitop
highli
immunogen
h
cell
help
induc
cytotox
cell
helper
cell
respons
weakli
immunogen
selfantigen
exampl
tetanu
toxin
tt
contain
epitop
avidli
bind
helper
cell
sever
preclin
studi
ttfuse
antigen
use
dna
vaccin
significantli
enhanc
immunogen
variou
cancer
antigen
includ
cmyb
pa
domain
contain
studi
demonstr
potenti
dna
vaccin
incorpor
tt
epitop
order
enhanc
immunogen
yang
et
al
break
central
immun
toler
critic
cancer
vaccin
efficaci
howev
break
toler
may
rais
risk
autoimmun
mani
cancer
antigen
also
express
normal
cell
albeit
low
level
enhanc
antigen
immunogen
expens
damag
normal
tissu
detriment
ontarget
offtumor
side
effect
report
cancer
treatment
use
adopt
transfer
genet
engin
cell
strategi
use
break
immun
toler
shown
trigger
harm
autoimmun
attack
normal
tissu
howev
studi
need
evalu
safeti
break
immun
toler
also
note
break
immun
toler
repres
one
greatest
obstacl
face
scientist
develop
effect
cancer
vaccin
factor
peripher
immunosuppress
network
includ
limit
myeloidderiv
suppressor
cell
mdsc
regulatori
cell
reg
inhibitori
cytokin
immun
exhaust
also
profoundli
affect
efficaci
dna
vaccin
therefor
agreement
notion
effect
cancer
therapi
multimod
clinic
develop
cancer
vaccin
may
ultim
part
polytherapi
eg
vaccin
checkpoint
blockad
mab
counteract
central
local
immunosuppress
mechan
numer
therapeut
dna
vaccin
current
evalu
clinic
trial
assess
translat
potenti
vaccin
target
wide
varieti
malign
includ
cervic
cancer
colorect
cancer
prostat
cancer
breast
cancer
head
neck
cancer
melanoma
merkel
cell
carcinoma
leukemia
summari
trial
includ
target
cancer
antigen
strategi
use
break
immun
toler
trial
stage
shown
tabl
tert
antigen
encod
dna
vaccin
synthes
codonoptim
two
immunogen
mutat
incorpor
htert
sequenc
assist
break
toler
date
success
encourag
outcom
use
dna
vaccin
clinic
set
obtain
treatment
malign
diseas
etiolog
agent
foreign
viral
origin
human
papillomaviru
hpv
viral
agent
readili
induc
strong
immun
respons
cancer
cell
harbor
viral
antigen
case
hpv
strain
identifi
caus
asymptomat
infect
howev
oncogen
highrisk
hpv
type
eg
shown
etiolog
agent
cervic
penil
vulvar
vagin
anal
oropharyng
cancer
particularli
regard
genotyp
close
associ
cervic
intraepitheli
neoplasia
cin
cervic
cancer
hpv
genom
encod
two
class
protein
includ
earli
e
late
l
protein
late
protein
structur
compon
viral
capsid
wherea
earli
protein
regulatori
protein
particip
dna
replic
transcript
regul
cell
transform
viral
assembl
among
viral
protein
inactiv
tumor
suppressor
retinoblastoma
rb
protein
respect
therebi
prevent
cellular
apoptosi
promot
cell
prolifer
contribut
progress
intraepitheli
neoplasia
carcinoma
moreov
express
hpvinfect
cell
constitut
irrespect
infect
stage
contrast
primari
infect
express
sever
earli
late
protein
becom
invis
result
delet
viral
gene
upon
viral
integr
host
genom
lin
et
al
therefor
owe
constitut
express
hpvassoci
malign
crucial
role
tumor
pathogenesi
protein
ideal
choic
hpv
antigen
develop
therapeut
vaccin
hpvassoci
malign
inde
sever
dna
vaccin
target
protein
test
clinic
trial
demonstr
impress
efficaci
evidenc
regress
high
grade
cin
normal
tissu
clearanc
viral
infect
last
year
great
progress
made
field
dna
vaccin
advanc
plasmid
construct
antigen
design
deliveri
devic
optim
use
immunolog
adjuv
greatli
enhanc
immunogen
efficaci
dna
vaccin
among
develop
electropor
repres
remark
progress
exert
greatest
impact
dna
vaccin
efficaci
recent
dna
vaccin
deliv
ep
demonstr
clinic
benefit
phase
iib
clinic
trial
form
regress
cervic
intraepitheli
neoplasia
encourag
result
led
resurg
platform
promis
improv
dna
immun
bring
revolutionari
transform
vaccin
field
end
scientist
work
dilig
toward
first
licensur
dna
vaccin
